DAVENPORT & Co LLC Buys New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

DAVENPORT & Co LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,982 shares of the medical research company's stock, valued at approximately $1,904,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CRL. VisionPoint Advisory Group LLC increased its position in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock valued at $28,000 after buying an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $37,000. Operose Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at approximately $42,000. Covestor Ltd increased its position in shares of Charles River Laboratories International by 100.0% in the first quarter. Covestor Ltd now owns 174 shares of the medical research company's stock valued at $49,000 after buying an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in shares of Charles River Laboratories International by 74.7% in the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock valued at $51,000 after buying an additional 112 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the company's stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares in the company, valued at approximately $3,437,635. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock worth $3,693,663 in the last quarter. 1.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. UBS Group lifted their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a "buy" rating in a research note on Thursday, February 15th. Robert W. Baird lifted their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an "outperform" rating in a research note on Thursday, February 15th. Guggenheim lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a "c+" rating to a "b-" rating in a research note on Friday, March 1st. Finally, Citigroup lifted their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.23.

Charles River Laboratories International Trading Up 1.0 %

Shares of Charles River Laboratories International stock traded up $2.44 during trading hours on Friday, hitting $253.10. The company's stock had a trading volume of 529,686 shares, compared to its average volume of 456,211. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The stock has a market cap of $13.04 billion, a price-to-earnings ratio of 27.48, a P/E/G ratio of 1.96 and a beta of 1.40. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The firm has a fifty day moving average of $249.73 and a 200-day moving average of $218.39.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. During the same quarter in the previous year, the business earned $2.98 EPS. The company's quarterly revenue was down 7.9% compared to the same quarter last year. Research analysts forecast that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).